
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sepiapterin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : PTC Therapeutics
Deal Size : $366.0 million
Deal Type : Acquisition
PTC Therapeutics to Acquire Censa Pharmaceuticals
Details : Censa Pharmaceuticals acquisition diversifies and strengthens PTC 's portfolio of rare disorders by adding the lead orphan metabolic disease drug, CNSA-001.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
May 06, 2020
Lead Product(s) : Sepiapterin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : PTC Therapeutics
Deal Size : $366.0 million
Deal Type : Acquisition
